September 9, 2013

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.

The following patent record is from the CAplusSM database.

CAPLUS COPYRIGHT 2013 ACS

Patent Number: US 8471010
Title: Synthesis of dihydrothieno[3,2-d]pyrimidine diols and similar pyrimidine diols
Inventor(s): Frutos, Rogelio Perez; Tampone, Thomas G.; Mulder, Jason Alan; Krishnamurthy, Dhileepkumar; Senanayake, Chris Hugh
Patent Assignee(s): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
Source: PCT Int. Appl., 43 pp. CODEN: PIXXD2
Language: English

Abstract:
The present invention relates to an improved process for the prepn. of dihydrothieno[3,2-d]pyrimidine diols I [R1, R2 = H, alkyl, cycloalkyl, aryl, etc.] and similar pyrimidine diols such as II [R3, R4 = H, alkyl, cycloalkyl, aryl, etc.; or R3 and R4 are combined with the carbon atoms to which they are attached to form (un)substituted benzene, pyridine, pyrimidine, etc.; R5 = H, alkyl, cyclolkyl, aryl, etc.], that is efficient, high-yielding, and does not require expensive and potentially unstable intermediates.  Compds. I were prepd. by reacting compd. III [R1 and R2 are defined as above; R = H, halo, alkyl, aryl] with urea in the presence of acid followed by cyclizing the resulting intermediate IV [R, R1, R2 are defined as above] with a base.  For example, reacting III [R1, R2 = H; R = Me] with urea in the presence of conc. HCl in MeOH followed by treating intermediate IV [R1, R2 = H; R = Me] with NaOH afforded I [R1, R2 = H].  The diols are used as intermediates in the synthesis of pyrimidine compds. which inhibit PDE4, and are thus useful in the treatment of respiratory or gastrointestinal diseases and complaints, peripheral or central nervous system diseases and disorders, inflammatory conditions, and cancers.

Please note:  Abstracts and Titles for patent records in CAplus are routinely enhanced to better describe the claimed invention.

 View the full-text here.

Recent News


    June 29, 2015 | CAS Assigns the 100 Millionth CAS
    Registry Number to a Substance Designed to
    Treat Acute Myeloid Leukemia
   
    March 17, 2015 | New Content Provides Regulatory
    Professionals with Additional Value

    February 9, 2015 | Major New STN Release Delivers
    Essential Biomedical and Patent Content to IP
    Professionals

                                                                       More News >> 
 
 

Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624
 Email: cas-pr@cas.org